Schizophrenia
2,952
196
233
2,045
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
682 trials with published results (23%)
Research Maturity
2045 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.2%
214 terminated out of 2952 trials
90.5%
+3.9% vs benchmark
27%
792 trials in Phase 3/4
33%
682 of 2045 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2045 completed trials
Clinical Trials (2952)
Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
Genetic Study of Schizophrenia
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
Effectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older Adults With Schizophrenia
Neuronavigated rTMS for Treatment-Resistant Auditory Hallucinations
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
iTBS to Enhance Social Cognition in People With Psychosis
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Effectiveness of mHealth Post-discharge Intervention for Patients With Severe Mental Illness
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia